Assertio Therapeutics is a drug manufacturers-specialty & generic business based in the US. Assertio Therapeutics shares (ASRT) are listed on the NASDAQ and all prices are listed in US Dollars. Assertio Therapeutics employs 19 staff and has a trailing 12-month revenue of around $139.2 million.
Finder Award
eToro
Finder Award
SoFi Invest
| Latest market close | $4.29 |
|---|---|
| 52-week range | $1.86 - $4.44 |
| 50-day moving average | $3.46 |
| 200-day moving average | $2.97 |
| Wall St. target price | $7.19 |
| PE ratio | 6.5556 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.54 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.29 from 2023-01-25
| 1 week (2023-01-19) | 15.01% |
|---|---|
| 1 month (2022-12-23) | 5.15% |
| 3 months (2022-10-26) | 75.10% |
| 6 months (2022-07-26) | 22.57% |
| 1 year (2022-01-26) | 88.16% |
|---|---|
| 2 years (2021-01-26) | 518.96% |
| 3 years (2020-01-24) | 283.04% |
| 5 years (2018-01-26) | 7.81 |
Valuing Assertio Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Assertio Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Assertio Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, Assertio Therapeutics shares trade at around 7x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Assertio Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.6155. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Assertio Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Assertio Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $86.8 million.
The EBITDA is a measure of a Assertio Therapeutics's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $139.2 million |
|---|---|
| Operating margin TTM | 39.08% |
| Gross profit TTM | $95.8 million |
| Return on assets TTM | 10.92% |
| Return on equity TTM | 22.16% |
| Profit margin | 18.45% |
| Book value | $2.80 |
| Market capitalisation | $171 million |
TTM: trailing 12 months
We're not expecting Assertio Therapeutics to pay a dividend over the next 12 months.
Assertio Therapeutics's shares were split on a 1:4 basis on 17 May 2021. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Assertio Therapeutics shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Assertio Therapeutics shares which in turn could have impacted Assertio Therapeutics's share price.
Over the last 12 months, Assertio Therapeutics's shares have ranged in value from as little as $1.86 up to $4.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Assertio Therapeutics's is 1.5051. This would suggest that Assertio Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Assertio Holdings, Inc. , a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
